The usage and dosage of Revumenib should be adjusted according to body weight and drug interactions. Special populations should pay attention to risk factors such as pregnancy, liver and kidney dysfunction when using Revumenib. The following provides a detailed explanation from two aspects: standard dosage regimen and medication for special populations, covering key points of clinical use.

1. Standard usage and dosage

Suggested oral administration, twice a day, can be taken on an empty stomach or with a low-fat meal. Individuals weighing ≥ 40kg who have not used strong CYP3A4 inhibitors: 270mg twice daily; Those who use strong CYP3A4 inhibitors should reduce their dosage to 160mg twice daily. Patients weighing less than 40kg should have their dosage calculated based on body surface area (BSA), with reference to 160mg/m ² or 95mg/m ² twice daily.

2. Medication for special populations

2.1 Pregnant women

There is a risk of embryotoxicity and its use should be avoided. Those who require medication must undergo a risk assessment and strictly use contraception during treatment and within one week after the last dose. Animal experiments have shown that it can cause fetal malformations, but human data is not yet sufficient.

2.2 Breastfeeding women

There is no data on the distribution of drugs in breast milk yet. It is recommended to stop breastfeeding during the treatment period and within one week after the last medication. It is necessary to weigh the impact of treatment necessity on mother and baby, and if necessary, adopt alternative feeding methods.

2.3 Child patients

Suitable for children aged ≥ 1 year, and for those weighing<40kg, the dosage should be calculated based on BSA. Monitoring of skeletal development is necessary as animal experiments have revealed a risk of premature closure of growth plates. The medication data for patients under 12 years old is limited and requires careful evaluation.

2.4 Elderly patients

The incidence of QTc prolongation and edema is slightly higher in people aged 65 and above. It is recommended to strengthen electrocardiogram monitoring. No routine dose adjustment is required, but individualized administration should be based on comorbidities and tolerability.

2.5 Liver dysfunction

Mild to moderate liver dysfunction (TBIL ≤ 3 × ULN) has no significant effect on drug exposure; The safety of use in patients with severe liver injury is not yet clear, and the risk benefit ratio needs to be carefully evaluated.

2.6 Renal insufficiency

Mild to moderate renal impairment (CLcr30-89mL/min) does not require dose adjustment; Severe and end-stage renal disease patients lack data and are not recommended for use.